CN1907507A - Lacrimal duct plug and its preparing process and use - Google Patents
Lacrimal duct plug and its preparing process and use Download PDFInfo
- Publication number
- CN1907507A CN1907507A CNA2006101126958A CN200610112695A CN1907507A CN 1907507 A CN1907507 A CN 1907507A CN A2006101126958 A CNA2006101126958 A CN A2006101126958A CN 200610112695 A CN200610112695 A CN 200610112695A CN 1907507 A CN1907507 A CN 1907507A
- Authority
- CN
- China
- Prior art keywords
- lacrimal duct
- duct plug
- solution
- chitosan
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a dacryosolen plug, relative preparation and application, wherein it materials are the collagen at 60-100 deals and one or two of following components as chitose at 1-20 deals and polyvinyl alcohol at 1-20 deals; the inventive product can function the lacrimal passage for 10-50 day, while the water adsorption force can reach 10mg/mg and the volume expanding rate can be over 10mm3/mm3; when it has been planted for 10mins, it will adsorb water, to radial expand into flexible cylinder, to block the lacrimal passage.
Description
Technical field
The present invention relates to a kind of lacrimal duct plug and preparation method thereof and application.
Background technology
Many ophthalmic diseasess are relevant with the amount of the excretory tear of ocular surface.These ophthalmic diseasess comprise xerophthalmia, corneal ulcer, conjunctivitis, blepharitis and many other eyes external disorders.Xerophthalmia is the modal clinically ophthalmic diseases that causes because of adacrya, the lighter shows as eye dryness, furious, burn feeling, foreign body sensation or eye sensation of aching, cornea diffusivity epithelium point-like or lamellar dyeing appear in weight person, go down for a long time and will cause ocular pain and blind.Whether normal secretion, tear evaporation, the tear of tear of depending on of surperficial at the moment tear and tear film discharged and tear composition and the complete aggregate balancing of level.
The Therapeutic Method of xerophthalmia, the lighter is mainly by artificial tears's (being collyrium) or hot compress etc.; Weight person needs lacrimal point or lacrimal duct plug art.The method of initial sealing lacrimal point is to use hot lacrimal point to burn, and this method is simple and effective, but can cause cicatrix, and pain is arranged, and is simultaneously irreversible.People used laser sealing lacrimal point afterwards, but observed according to long term follow-up, and 20% postoperative lacrimal point is opened again, and the advantage of the more hot inustion of laser method is the lacrimal point cicatrix can not occur.But the thromboembolism that is used to block tear stains is divided into absorption-type and can not absorption-type.For the xerophthalmia patient, use the former usually earlier.When doing well,improving or disappearance and patient do not have the difference sense, can further use the latter of permanent type.The former is bar-shaped, degraded and absorbed in the week; The latter is top cap type or horn, and non-degradable absorbs, and also need change because of after wearing and tearing 3 months.Learn through clinic trial, less because of compatriots' fissura palpebrae, go up the tight or eyelid of palpebra inferior towards eyeball, use the top cap type or the horn tear stains bolt of U.S. Medennium or CIBA Vision company just might make its top cover and bulbar conjunctiva friction, cause foreign body sensation, be not suitable for compatriots' eye structure characteristics, and cost an arm and a leg.
Summary of the invention
The purpose of this invention is to provide a kind of lacrimal duct plug and preparation method thereof and application.
Lacrimal duct plug provided by the present invention, the raw material of making it are any one or two kinds in 60-100 weight portion collagen protein and the following two kinds of compositions: 1-20 weight portion chitosan and 1-20 weight account polyethylene alcohol.
The raw material of making described lacrimal duct plug can be 1-20 weight fraction chitosan and 99-80 weight fraction collagen protein.
The raw material of making described lacrimal duct plug also can be 1-20 weight fraction polyvinyl alcohol and 99-80 weight fraction collagen protein.
The raw material of making described lacrimal duct plug also can be 1-20 weight portion chitosan, the pure and mild 60-98 weight portion of 1-20 weight account polyethylene collagen protein.
The deacetylation of described chitosan is 70-90%, and viscosity-average molecular weight is (1.0-4.0) * 10
5
The degree of polymerization of described polyvinyl alcohol is 1500-2000.
Described collagen protein wide material sources can obtain from commercial channels, can be that disclosed method obtains in 01142070.7 the patent according to the patent No. also.Above-mentioned collagen protein mainly is made up of type i collagen, has the distinctive three-dimensional spiral structure of collagen.
The preparation method of lacrimal duct plug provided by the present invention may further comprise the steps:
1) chitosan is dissolved in makes the chitosan solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%; And/or be made into the poly-vinyl alcohol solution that mass percentage concentration is 1-4% with polyvinyl alcohol is soluble in water; Collagen protein is dissolved in is made into the collagen solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%;
2) two or three solution that step 1) is disposed is the aforementioned proportion mixing by the ratio of weight and number of chitosan and/or polyvinyl alcohol and collagen protein, makes clava; Clava fixedly obtained lacrimal duct plug in 20-40 minute then in exposing 20-100 minute under the room temperature in the alkaline steam environment in the aldehyde material steam ambient under the room temperature.
In the described method, described step 2) aldehyde material is formaldehyde and/or Biformyl and/or glutaraldehyde in.Above-mentioned aldehyde material volume ratio arbitrarily mixes.
In the described method, described step 2) the neutral and alkali steam ambient can be the steam that the solution of caustic soda (sodium hydroxide) and/or caustic potash (potassium hydroxide) and/or sodium carbonate and/or sodium bicarbonate forms.The pH value of the solution of described caustic soda (sodium hydroxide) and/or caustic potash (potassium hydroxide) and/or sodium carbonate and/or sodium bicarbonate is 9-13.Above-mentioned alkaline matter volume ratio arbitrarily mixes.
In the described method, acid solution is formic acid, acetic acid, propanoic acid or hydrochloric acid solution in the described step 1).
The deacetylation of described chitosan is 70-90%, and viscosity-average molecular weight is (1.0-4.0) * 10
5
The degree of polymerization of described polyvinyl alcohol is 1500-2000.
Described method also comprises step 2) lacrimal duct plug that obtains uses
60The Co radiation sterilization.
Described lacrimal duct plug length is that 2mm, diameter are 0.3-0.8mm.
Lacrimal duct plug of the present invention is a base material with chitosan and/or polyvinyl alcohol and collagen protein, cross-linking modified through structure, lacrimal duct plug can reach 10-50 days at lacrimal passage action time, be better than existing absorbable temporary pattern product on the market (absorbing in 1 week), the sense of discomfort that the permanent type product of having avoided use to absorb causes compatriots' eyelid.Lacrimal duct plug of the present invention, water absorbing force reach about 10mg/mg, and cubical expansivity surpasses 10mm
3/ mm
3The lacrimal duct plug that the present invention makes, lacrimal passage is very hard before implanting, and is convenient to clinical manipulation; Implant suction gradually in back 10 minutes, expand into softish cylinder diametrically, play mechanical ponding.
The method for preparing lacrimal duct plug of the present invention is used alkali steam neutralisation treatment and aldehyde material steam treatment in the thromboembolism course of processing, improved the biocompatibility of lacrimal duct plug, makes product acid basicity near neutral human body environment.The cross-linking agent steam treatment has avoided the impurity in the cross-linking agent solution to be incorporated in the product.
The specific embodiment
Method among the following embodiment if no special instructions, is conventional method.
Percentage composition described in the following method if no special instructions, is the quality percentage composition.
The preparation of embodiment 1, collagen base lacrimal duct plug
With deacetylation 80%, viscosity-average molecular weight 2 * 10
5Chitosan be dissolved in 0.01% the hydrochloric acid solution, make chitosan concentration and be 2% solution.Collagen protein (being the method preparation of step 1-8 among the embodiment 1 of 01142070.7 patent according to the patent No.) is dissolved in 0.01% the hydrochloric acid solution, obtains collagen concentration and be 2% solution.With above-mentioned chitosan solution and collagen solution, be that 1: 9 mixed is even by chitosan and collagen protein quality ratio.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that the 0.2mol/L sodium carbonate liquor forms and expose 30 minutes, in formaldehyde gas, expose 25 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug I.
In the chemically inert hermetic container of cleaning, add 50 above-mentioned thromboembolism I and 10ml distilled water, at 37 ℃ of lixiviate 72h ± 2h; Lixiviating solution is 7.1 by the pH value that 5.4 methods among the GB/T 14233.1-1998 record collagen base lacrimal duct plug I.
(quality is W to 10 collagen base lacrimal duct plug I samples that precision is weighed
1), put into the beaker that fills distilled water, make moisture fully immerse sample, extrude bubble in the sample with Glass rod gently.Press from both sides out sample gently with the ophthalmology tweezers from water, precision is weighed, and (quality is W
2).Press following formula: w=(W
2-W
1)/W
1The water absorbing force that records collagen base lacrimal duct plug I is 10.5mg/mg.
Get 10 collagen base lacrimal duct plug I samples, calculate volume (V by cylinder with precimeter
1).Put into the beaker that fills distilled water then, make moisture fully immerse sample, extrude bubble in the sample with Glass rod gently.From water, press from both sides out sample gently with the ophthalmology tweezers, on calibrator, measure the diameter and the length of immersion sample, calculate the volume (V of immersion sample thus
2).Press following formula: v=(V
2-V
1)/V
1, recording collagen base lacrimal duct plug I cubical expansivity is 13mm
3/ mm
3
The preparation of embodiment 2, collagen base lacrimal duct plug
With deacetylation 80%, viscosity-average molecular weight 2 * 10
5Chitosan be dissolved in 1% the hydrochloric acid solution, make chitosan concentration and be 4% solution.Collagen protein (available from Hechuan, Guangzhou bio tech ltd) is dissolved in 1% the hydrochloric acid solution, obtains collagen concentration and be 4% solution.With above-mentioned chitosan solution and collagen solution, be that 1: 4 mixed is even by chitosan and collagen protein quality ratio.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that the 0.2mol/L sodium carbonate liquor forms and expose 30 minutes, exposure 25 minutes in the mist (formaldehyde and Biformyl volume ratio are 1: 1) of formaldehyde and Biformyl again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug II.
The pH value that records collagen base lacrimal duct plug II with the method for embodiment 1 is 7.2.
The water absorbing force that records collagen base lacrimal duct plug II with the method for embodiment 1 is 9.5mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug II with the method for embodiment 1 is 12mm
3/ mm
3
The preparation of embodiment 3, collagen base lacrimal duct plug
With deacetylation 80%, viscosity-average molecular weight 2 * 10
5Chitosan be dissolved in 0.001% the hydrochloric acid solution, make chitosan concentration and be 1% solution.Collagen protein (available from Canadian biological engineering development company) is dissolved in 0.001% the hydrochloric acid solution, obtains collagen concentration and be 1% solution.With above-mentioned chitosan solution and collagen solution, be that 1: 99 mixed is even by chitosan and collagen protein quality ratio.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that the 0.2mol/L sodium carbonate liquor forms and expose 30 minutes, in formaldehyde gas, expose 25 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug III.
The pH value that records collagen base lacrimal duct plug III with the method for embodiment 1 is 6.8.
The water absorbing force that records collagen base lacrimal duct plug III with the method for embodiment 1 is 10.8mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug III with the method for embodiment 1 is 15mm
3/ mm
3
The preparation of embodiment 4, collagen base lacrimal duct plug
With the degree of polymerization is that 1800 polyvinyl alcohol is soluble in water, makes polyvinyl alcohol concentration and be 2% solution.Collagen protein is dissolved in 0.01% the propanoic acid, obtaining collagen protein (being the method preparation of step 1-8 among the embodiment 1 of 01142070.7 patent according to the patent No.) concentration is 2% solution.With above-mentioned polyvinyl alcohol and collagen solution, be that 1: 9 mixed is even by the mass ratio of polyvinyl alcohol and collagen protein.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that 0.02mol/L caustic potash (potassium hydroxide) solution forms and expose 40 minutes, in Biformyl gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug IV.
The pH value that records collagen base lacrimal duct plug IV with the method for embodiment 1 is 6.9.
The water absorbing force that records collagen base lacrimal duct plug IV with the method for embodiment 1 is 10.5mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug IV with the method for embodiment 1 is 14mm
3/ mm
3
The preparation of embodiment 5, collagen base lacrimal duct plug
With the degree of polymerization is that 1800 polyvinyl alcohol is soluble in water, makes polyvinyl alcohol concentration and be 3% solution.Collagen protein is dissolved in 0.001% the propanoic acid, obtaining collagen protein (available from benefit health Science and Technology Ltd. of Harbin Institute of Technology) concentration is 2% solution.With above-mentioned polyvinyl alcohol and collagen solution, be that 1: 4 mixed is even by the mass ratio of polyvinyl alcohol and collagen protein.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that 0.002mol/L caustic potash (potassium hydroxide) solution forms and expose 40 minutes, in Biformyl gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug V.
The pH value that records collagen base lacrimal duct plug V with the method for embodiment 1 is 7.0.
The water absorbing force that records collagen base lacrimal duct plug V with the method for embodiment 1 is 10.4mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug V with the method for embodiment 1 is 11mm
3/ mm
3
The preparation of embodiment 6, collagen base lacrimal duct plug
With the degree of polymerization is that 1800 polyvinyl alcohol is soluble in water, makes polyvinyl alcohol concentration and be 2% solution.Collagen protein is dissolved in 0.01% the propanoic acid, obtaining collagen protein (available from the clean biochemical industry company limited of Shanghai dream) concentration is 2% solution.With above-mentioned polyvinyl alcohol and collagen solution, be that 1: 99 mixed is even by the mass ratio of polyvinyl alcohol and collagen protein.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that caustic potash (0.02mol/L) and sodium hydroxide (0.02mol/L) mixed solution form and expose 40 minutes, in Biformyl gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug VI.
The pH value that records collagen base lacrimal duct plug VI with the method for embodiment 1 is 6.8.
The water absorbing force that records collagen base lacrimal duct plug VI with the method for embodiment 1 is 10.7mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug VI with the method for embodiment 1 is 15mm
3/ mm
3
The preparation of embodiment 7, collagen base lacrimal duct plug
With deacetylation 80%, viscosity-average molecular weight 2 * 10
5Chitosan be dissolved in 0.05% the acetic acid solution, make chitosan concentration and be 2% solution.With the degree of polymerization is that 1500 polyvinyl alcohol is soluble in water, makes polyvinyl alcohol concentration and be 2% solution.Collagen protein (available from the clean biochemical industry company limited of Shanghai dream) is dissolved in 0.05% the acetic acid solution, obtains collagen concentration and be 2% solution.With above-mentioned chitosan, polyvinyl alcohol and collagen solution, be that 1: 1: 8 mixed is even by the mass ratio of chitosan, polyvinyl alcohol and collagen protein.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that 0.1mol/L caustic soda and 0.5mol/L sodium carbonate mixture form and expose 20 minutes, in glutaraldehyde gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug VII.
The pH value that records collagen base lacrimal duct plug VII with the method for embodiment 1 is 7.0.
The water absorbing force that records collagen base lacrimal duct plug VII with the method for embodiment 1 is 10.1mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug VII with the method for embodiment 1 is 15mm
3/ mm
3
The preparation of embodiment 8, collagen base lacrimal duct plug
With deacetylation 75%, viscosity-average molecular weight 4 * 10
5Chitosan be dissolved in 0.01% the hydrochloric acid solution, make chitosan concentration and be 3% solution.The polyvinyl alcohol of the degree of polymerization 1900 is soluble in water, make polyvinyl alcohol concentration and be 3% solution.Collagen protein (being the method preparation of step 1-8 among the embodiment 1 of 01142070.7 patent according to the patent No.) is dissolved in 0.01% the hydrochloric acid solution, obtains collagen concentration and be 3% solution.With above-mentioned chitosan, polyvinyl alcohol and collagen solution, by chitosan, polyvinyl alcohol and collagen protein quality ratio is that 1.5: 1.5: 7 mixed are even, extrude or be injected into clava, clava is introduced in the hermetic container of the alkali steam that the 0.5mol/L soda lye forms and exposes 20 minutes, in formaldehyde gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug VIII.
The pH value that records collagen base lacrimal duct plug VIII with the method for embodiment 1 is 7.2.
The water absorbing force that records collagen base lacrimal duct plug VIII with the method for embodiment 1 is 11.3mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug VIII with the method for embodiment 1 is 14mm
3/ mm
3
The preparation of embodiment 9, collagen base lacrimal duct plug
With deacetylation 80%, viscosity-average molecular weight 2 * 10
5Chitosan be dissolved in 0.05% the acetic acid solution, make chitosan concentration and be 4% solution.With the degree of polymerization is that 1500 polyvinyl alcohol is soluble in water, makes polyvinyl alcohol concentration and be 4% solution.Collagen protein (available from the clean biochemical industry company limited of Shanghai dream) is dissolved in 0.05% the acetic acid solution, obtains collagen concentration and be 4% solution.With above-mentioned chitosan, polyvinyl alcohol and collagen solution, be that 1: 1: 3 mixed is even by the mass ratio of chitosan, polyvinyl alcohol and collagen protein.Extrude or be injected into clava, be introduced in the hermetic container of the alkali steam that 0.1mol/L caustic soda and 0.5mol/L sodium carbonate mixture form and expose 20 minutes, in glutaraldehyde gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug IX.
The pH value that records collagen base lacrimal duct plug IX with the method for embodiment 1 is 7.5.
The water absorbing force that records collagen base lacrimal duct plug IX with the method for embodiment 1 is 12.3mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug IX with the method for embodiment 1 is 11mm
3/ mm
3
The preparation of embodiment 10, collagen base lacrimal duct plug
With deacetylation 75%, viscosity-average molecular weight 4 * 10
5Chitosan be dissolved in 0.01% the hydrochloric acid solution, make chitosan concentration and be 3% solution.The polyvinyl alcohol of the degree of polymerization 1900 is soluble in water, make polyvinyl alcohol concentration and be 3% solution.Collagen protein (available from Harbin Institute of Technology benefit health Science and Technology Ltd.) is dissolved in 0.01% the hydrochloric acid solution, obtains collagen concentration and be 3% solution.With above-mentioned chitosan, polyvinyl alcohol and collagen solution, by chitosan, polyvinyl alcohol and collagen protein quality ratio is that 1: 1: 98 mixed is even, extrude or be injected into clava, clava is introduced in the hermetic container of the alkali steam that the 0.5mol/L soda lye forms and exposes 20 minutes, in formaldehyde gas, expose 30 minutes again.The collagen base lacrimal duct plug that obtains is through the paper airtight package,
60The Co radiation sterilization final products collagen base lacrimal duct plug X.
The pH value that records collagen base lacrimal duct plug X with the method for embodiment 1 is 6.9.
The water absorbing force that records collagen base lacrimal duct plug X with the method for embodiment 1 is 9.6mg/mg.
The cubical expansivity that records collagen base lacrimal duct plug X with the method for embodiment 1 is 16mm
3/ mm
3
The clinical effectiveness experiment of embodiment 11, collagen base lacrimal duct plug
Under slit lamp microscope, to survey in the face eyelid down with pointing compressing gently, exposure is lacrimal point down, and lacrimal passage (point) is inserted gently with its other end in the end that another hand-held ophthalmology tweezers are clamped the collagen thromboembolism, until loseing.Carry out clinical experiment with collagen base lacrimal duct plug I-X of the present invention, the result shows that tear all increased in the aggregate amount of eyeball after collagen base lacrimal duct plug I-X performed the operation 10 minutes.
Estimate the clinical effectiveness method of collagen base lacrimal duct plug treatment xerophthalmia: select the patient that is diagnosed as xerophthalmia and gets rid of the lacrimal passage disease at random, divide 10 groups, every group 6 example, 20 years old-65 years old age is average 50.4 ± 8.9 years old.Respectively with collagen base lacrimal duct plug I, collagen base lacrimal duct plug II, collagen base lacrimal duct plug III, collagen base lacrimal duct plug IV, collagen base lacrimal duct plug V, collagen base lacrimal duct plug VI, collagen base lacrimal duct plug VII, collagen base lacrimal duct plug VIII, collagen base lacrimal duct plug IX, the collagen base lacrimal duct plug X treatment that undergos surgery.The result shows that above-mentioned collagen base lacrimal duct plug I-X is after treatment, and all there is improvement the tear amount and the tear membrane stability aspect of the test of carbolic acid red line, breakup time of tear film (TBUT), angle conjunctiva fluorescent staining inspection.The result is as follows before and after the treatment.Case follow-up observation through 2 months learns that collagen base lacrimal duct plug I-X is respectively 15,39,45,20 in the lacrimal passage mean effort time, 35d, 38d, 45d, 50d, 49d, 50d.
Collagen base lacrimal duct plug I-X is as shown in table 1 in the result of the test of carbonic acid red line, breakup time of tear film (TBUT), angle conjunctiva fluorescent staining tear amount and tear membrane stability.
The effect experiment of table 1. collagen base lacrimal duct plug I-X
| Test event | The test of carbonic acid red line | Breakup time of tear film | Angle conjunctiva fluorescent staining check result | |||
| Collagen base lacrimal duct plug | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment (positive rate) | Treatment back (positive rate) |
| I | 5.01± 1.64mm | 9.69± 2.37mm | 3.45± 1.09s | 9.49± 2.29s | 93.3％ | 73.3％ |
| II | 4.91± 1.34mm | 9.99± 2.03mm | 3.36± 1.07s | 9.55± 2.09s | 97.2％ | 73.5％ |
| III | 5.20± 1.05mm | 9.26± 2.37mm | 3.56± 1.39s | 9.63± 2.35s | 92.1％ | 70.3％ |
| IV | 5.15± 0.96mm | 9.83± 2.36mm | 3.66± 1.13s | 9.85± 2.01?s | 94.1％ | 71.2％ |
| V | 4.99± 1.77mm | 9.87± 1.99mm | 3.39± 1.09s | 9.65± 2.33s | 95.5％ | 71.3％ |
| VI | 5.03± 1.44mm | 9.96± 1.89mm | 3.69± 1.00s | 9.95± 2.29s | 98.2％ | 69.9％ |
| VII | 4.93± 1.59mm | 10.66± 2.01mm | 3.35± 1.06s | 10.39± 2.12s | 95.9％ | 60.5％ |
| VIII | 5.53± 1.66mm | 10.86± 2.03mm | 3.65± 1.33s | 11.19± 1.39s | 93.7％ | 61.2％ |
| IX | 5.25± 1.76mm | 10.01± 2.00mm | 3.35± 1.26s | 10.95± 2.36s | 95.7％ | 60.1％ |
| X | 5.33± 1.22mm | 10.31± 1.99mm | 3.38± 1.29s | 10.68± 2.07s | 97.3％ | 62.4％ |
Claims (10)
1, a kind of lacrimal duct plug, the raw material of making it are any one or two kinds in 60-100 weight portion collagen protein and the following two kinds of compositions: 1-20 weight portion chitosan and 1-20 weight account polyethylene alcohol.
2, lacrimal duct plug according to claim 1 is characterized in that: the described raw material of making lacrimal duct plug is 1-20 weight fraction chitosan and 99-80 weight fraction collagen protein.
3, lacrimal duct plug according to claim 1 is characterized in that: the described raw material of making lacrimal duct plug is 1-20 weight fraction polyvinyl alcohol and 99-80 weight fraction collagen protein.
4, lacrimal duct plug according to claim 1 is characterized in that: the described raw material of making lacrimal duct plug is 1-20 weight portion chitosan, the pure and mild 60-98 weight portion of 1-20 weight account polyethylene collagen protein.
5, according to the arbitrary described lacrimal duct plug of claim 1-4, it is characterized in that: the deacetylation of described chitosan is 70-90%, and viscosity-average molecular weight is 1.0 * 10
5-4.0 * 10
5The degree of polymerization of described polyvinyl alcohol is 1500-2000.
6, according to arbitrary described lacrimal duct plug among the claim 1-5, it is characterized in that: the preparation method of described lacrimal duct plug may further comprise the steps:
1) chitosan is dissolved in makes the solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%; And/or be made into the solution that mass percentage concentration is 1-4% with polyvinyl alcohol is soluble in water; Collagen protein is dissolved in is made into the solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%;
2) two or three solution of step 1) configuration is pressed the chitosan described in the claim 1 or 2 or 3 or 4 or 5 and/or the ratio of weight and number mixing of polyvinyl alcohol and collagen protein, make clava; Clava fixedly obtained lacrimal duct plug in 20-40 minute then in exposing 20-100 minute under the room temperature in the alkaline steam environment in the aldehyde material steam ambient under the room temperature.
7, according to the lacrimal duct plug described in the claim 6, it is characterized in that: in the preparation method of described lacrimal duct plug, described aldehyde material is formaldehyde and/or Biformyl and/or glutaraldehyde; Described alkaline steam environment is the steam that the solution of caustic soda and/or caustic potash and/or sodium carbonate and/or sodium bicarbonate forms; Described acid solution is formic acid, acetic acid, propanoic acid or hydrochloric acid solution.
8, a kind of preparation method of lacrimal duct plug may further comprise the steps:
1) chitosan is dissolved in makes the solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%; And/or be made into the solution that mass percentage concentration is 1-4% with polyvinyl alcohol is soluble in water; Collagen protein is dissolved in is made into the solution that mass percentage concentration is 1-4% in the acid solution that mass percentage concentration is 0.001-1%;
2) two or three solution of step 1) configuration is pressed the chitosan described in the claim 1 or 2 or 3 or 4 or 5 and/or the ratio of weight and number mixing of polyvinyl alcohol and collagen protein, make clava; Clava fixedly obtained lacrimal duct plug in 20-40 minute then in exposing 20-100 minute under the room temperature in the alkaline steam environment in the aldehyde material steam ambient under the room temperature.
9, method according to claim 8 is characterized in that: described aldehyde material is formaldehyde and/or Biformyl and/or glutaraldehyde; Described alkaline steam environment is the steam that the solution of caustic soda and/or caustic potash and/or sodium carbonate and/or sodium bicarbonate forms; Described acid solution is formic acid, acetic acid, propanoic acid or hydrochloric acid solution; The deacetylation of described chitosan is 70-90%, and viscosity-average molecular weight is 1.0 * 10
5-4.0 * 10
5The degree of polymerization of described polyvinyl alcohol is 1500-2000.
10, method according to claim 9 is characterized in that: described method also comprises step 2) lacrimal duct plug that obtains sterilizes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101126958A CN100413547C (en) | 2006-08-30 | 2006-08-30 | Lacrimal duct plug and its preparing process and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101126958A CN100413547C (en) | 2006-08-30 | 2006-08-30 | Lacrimal duct plug and its preparing process and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1907507A true CN1907507A (en) | 2007-02-07 |
| CN100413547C CN100413547C (en) | 2008-08-27 |
Family
ID=37698845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101126958A Expired - Fee Related CN100413547C (en) | 2006-08-30 | 2006-08-30 | Lacrimal duct plug and its preparing process and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100413547C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396339B (en) * | 2008-10-20 | 2010-04-14 | 何伟 | Novel degradable lacrimal passage plug and preparation method thereof |
| CN101969897A (en) * | 2007-09-07 | 2011-02-09 | Qlt栓塞输送公司 | Insertion and extraction tools for lacrimal implants |
| CN101683538B (en) * | 2008-09-28 | 2013-01-02 | 上海市第十人民医院 | Lacrimal passage stopper and preparation method thereof |
| CN104623741A (en) * | 2008-04-30 | 2015-05-20 | 马缇医疗股份有限公司 | Composite lacrimal insert and related methods |
| CN104984410A (en) * | 2015-07-29 | 2015-10-21 | 陕西博与再生医学有限公司 | Controllable-degradation lacrimal passage suppository and preparation method thereof |
| CN109821056A (en) * | 2019-02-21 | 2019-05-31 | 南方科技大学 | Embolic agent and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5163959A (en) * | 1990-03-29 | 1992-11-17 | Herrick Robert S | Method for treating an eye with a canalicular implant having a collapsible flared section |
| CN1234424C (en) * | 2001-09-10 | 2006-01-04 | 中国人民解放军军事医学科学院卫生装备研究所 | Collagen based composite sponge and production thereof |
| US20080038317A1 (en) * | 2004-09-10 | 2008-02-14 | Chin-Ming Chang | Therapeutic Lacrimal Canalicular Inserts And Related Methods |
| CN100350978C (en) * | 2005-07-12 | 2007-11-28 | 何伟 | Medicine-carried degradable type lacrimal duct embolus, and its prepn. method |
| CN1760231A (en) * | 2005-10-13 | 2006-04-19 | 同济大学 | The preparation method who is used for the degradable high polymer material of lacrimal point bolt |
-
2006
- 2006-08-30 CN CNB2006101126958A patent/CN100413547C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101969897A (en) * | 2007-09-07 | 2011-02-09 | Qlt栓塞输送公司 | Insertion and extraction tools for lacrimal implants |
| CN104623741A (en) * | 2008-04-30 | 2015-05-20 | 马缇医疗股份有限公司 | Composite lacrimal insert and related methods |
| CN101683538B (en) * | 2008-09-28 | 2013-01-02 | 上海市第十人民医院 | Lacrimal passage stopper and preparation method thereof |
| CN101396339B (en) * | 2008-10-20 | 2010-04-14 | 何伟 | Novel degradable lacrimal passage plug and preparation method thereof |
| CN104984410A (en) * | 2015-07-29 | 2015-10-21 | 陕西博与再生医学有限公司 | Controllable-degradation lacrimal passage suppository and preparation method thereof |
| CN109821056A (en) * | 2019-02-21 | 2019-05-31 | 南方科技大学 | Embolic agent and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100413547C (en) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1310651C (en) | Pharmaceutical composition for use in ophthalmology and rhinology | |
| CN1907507A (en) | Lacrimal duct plug and its preparing process and use | |
| CN1185009C (en) | Eye preparation | |
| CN1326352A (en) | Hyaluronic acid gel, process for preparation thereof and medical materials containing the same | |
| CN1344168A (en) | Ophthalmic compsns. | |
| WO2014032804A1 (en) | Sterilised composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate | |
| JP4870944B2 (en) | Ophthalmic composition | |
| JPWO2008001872A1 (en) | Ophthalmic composition containing alginic acid or a salt thereof | |
| CN113795242A (en) | Dissolvable polymeric ocular inserts and methods of use thereof | |
| RU2712271C2 (en) | Chitosan-containing composition sterilized by heating, as well as method for production thereof | |
| CN1604784A (en) | Heparin-containing ophthalmic agent | |
| CN1823754A (en) | Sodium bromophenolate eye drops and its preparation method | |
| JP5616617B2 (en) | Eye drops for silicone hydrogel contact lenses | |
| CN115605270A (en) | Physically mixed HA-collagen dermal filler | |
| JP2019006810A (en) | Eye drops for silicone hydrogel contact lenses | |
| EP2254584B1 (en) | Biocompatible injectable products with zinc and/or zinc-form saccharide-salt release, and uses thereof | |
| JP5611216B2 (en) | Composition for prevention or treatment of eye diseases | |
| CN1132585C (en) | Water soluble medical chitose preparation and its preparation | |
| RU2012126633A (en) | METHOD FOR SCREENING AN AGENT SUITABLE FOR TREATING A DRY EYE SYNDROME AND / OR CORNEAL AND CONJUNCTIVES, PHARMACEUTICAL COMPOSITION OBTAINED WITH THIS METHOD | |
| CN1857506A (en) | Instant cordate houttuynia gel preparation for eye and its preparing method | |
| CN1814299A (en) | Macrolide antibiotics sodium hyaluronate eye transfer system | |
| CN101396339B (en) | Novel degradable lacrimal passage plug and preparation method thereof | |
| CN1883507A (en) | An effervescence tablet of cold-treating preparation and preparation method thereof | |
| CN1899286A (en) | Racanisodamine eye drops | |
| CN1246333A (en) | Polycarboxylic acid polymer used for treating vaginal infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080827 Termination date: 20130830 |